Zheng Zeng
Harbin Medical University, China
Title: END and ENL inhibit the proliferation, migration and invasiveness of ovarian cancer
Biography
Biography: Zheng Zeng
Abstract
Ovarian carcinoma is the third most common malignancy and the fifth most fatal cancer among the gynecological cancers. Those of the epithelial origin account for 80%−90% of all types of ovarian cancer and are the deadliest, giving rise to 5-year survival rates of the patients lower than 30%. At present, chemotherapy is still among the most important treatment strategies along with surgery and radiotherapy, but drug resistance, poor prognosis and tumor recurrence remain to be the overwhelming challenges. Over the past years, natural substances, such as the mammalian lignans enterodiol (END) and enterolactone (ENL), have gained attention for their excellent activities against a broad range of cancers and low side effects. However, whether END or ENL can inhibit ovarian cancers is not clear. In this study, we found that the proliferation, migration and invasion characteristics of epithelial ovarian cancer derived ES-2 cells were severely limited by ENL and END in an incremental dose and time pattern. In the parallel tumor-bearing mouse model, ENL exhibited more effective tumor-suppressing capability and less side effects than END. These findings may help develop novel strategies for the treatment of ovarian cancers by the use of ENL and END.